DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Metastatic Colorectal Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Colorectal Cancer Pipeline Outlook
Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
- In October 2024:- Buzzard Pharmaceuticals- A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination with Pembrolizumab in Patients with Metastatic or Unresectable, Locally Advanced Colorectal Cancer. In this study the investoigators are testing a new type of immunotherapy aclled isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this otherwise effective treatment to work on this treatment resistant type of tumor.
- In October 2024:- AbbVie- An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer.
- DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Metastatic Colorectal Cancer treatment.
- The leading Metastatic Colorectal Cancer Companies such as Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech, and others.
- Promising Metastatic Colorectal Cancer Therapies such as Encorafenib, Cetuximab, NPX267, MRTX849, Cetuximab, TNO155, BXQ-350, and others
Stay ahead with the most recent pipeline outlook for Metastatic Colorectal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Colorectal Cancer Treatment Drugs
Metastatic Colorectal Cancer Emerging Drugs Profile
- Lumakras (sotorasib): Amgen
Lumakras (sotorasib) is a highly selective inhibitor of KRAS G12C that potentially suppresses the rapid proliferation of cancer cells. Sotorasib forms an irreversible, covalent bond with the cysteine residue of KRAS G12C, holding the protein in its inactive form that blocks the oncogenic signaling. This results in apoptosis only in KRAS G12C tumor cell. It is being investigated as a treatment for a variety of solid tumors, including NSCLC, colorectal cancer and other solid tumor cancers. Currently, the drug is in the Phase III stage of its development for the treatment of Metastatic Colorectal Cancer.
- Axitinib: Pfizer
Axitinib is an oral therapy that is designed to inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3; these receptors can influence tumor growth, vascular angiogenesis and progression of cancer. In the U.S., INLYTA is approved for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. Currently, the drug is in the Phase II stage of its development for the treatment of Metastatic Colorectal Cancer.
- NX 1607: Nurix Therapeutics Inc
NX-1607 is an orally bioavailable inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types. NX-1607 acts on T cells, NK cells, and dendritic cells to enhance anti-tumor immunity, and has demonstrated single-agent anti-tumor activity in multiple tumor models. Nurix is evaluating NX-1607 in an ongoing, Phase I dose escalation and expansion trial in adults with a variety of oncology indications at multiple clinical sites. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.
- TP-1454: Sumitomo Dainippon Pharma Oncology
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator that is currently being evaluated in a Phase I/I b study in patients with advanced metastatic or progressive solid tumors. TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment. Currently, the drug is in the Phase I stage of its development for the treatment of Metastatic Colorectal Cancer.
Explore groundbreaking therapies and clinical trials in the Metastatic Colorectal Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Colorectal Cancer Drugs
Metastatic colorectal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Unveil the future of Metastatic Colorectal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Colorectal Cancer Market Drivers and Barriers
Scope of the Metastatic Colorectal Cancer Pipeline Report
- Coverage- Global
- Metastatic Colorectal Cancer Companies- Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi Sankyo, Qilu Pharmaceutical Co., Ltd., Binhui Biopharmaceutical, Parasol Biotech, Syndax Pharmaceuticals, Innovative Cellular Therapeutics, Immvira Pharma, ISA Pharmaceuticals, Jiangsu Hengrui Medicine, Peptomyc, Xbrane, TransCode Therapeutics, Servier, Jemincare, XBiotech, and others.
- Metastatic Colorectal Cancer Therapies- Encorafenib, Cetuximab, NPX267, MRTX849, Cetuximab, TNO155, BXQ-350, and others.
- Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Metastatic Colorectal Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Colorectal Cancer Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Metastatic colorectal cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Metastatic colorectal cancer Collaboration Deals
- Late Stage Products (Phase III)
- Lumakras (sotorasib): Amgen
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Axitinib: Pfizer
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- NX 1607: Nurix Therapeutics Inc
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic colorectal cancer Key Companies
- Metastatic colorectal cancer Key Products
- Metastatic colorectal cancer- Unmet Needs
- Metastatic colorectal cancer- Market Drivers and Barriers
- Metastatic colorectal cancer- Future Perspectives and Conclusion
- Metastatic Colorectal Cancer Analyst Views
- Metastatic Colorectal Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/